No Data
Lushang Freda Pharmaceutical (600223.SH): Its two main brands, Aier Doctor and Yilian, have both settled in WeChat's small store.
According to Gelonghui on December 31, Lushang Freda Pharmaceutical (600223.SH) stated on the investor interaction platform that its two main brands, All Doctor and Yilian, have both entered WeChat's small store, fully connecting multiple traffic entrances such as public accounts, video accounts, search, and mini programs. Guangxi Tencent Venture Capital Co., Ltd. Holds 8.04% equity in the company’s subsidiary, ShanDong Lushang Freda Bio-Technology Co., Ltd.
Lushang Freda Pharmaceutical (600223.SH): Currently has no involvement in Retirement business.
Gelonghui reported on December 27 that Lushang Freda Pharmaceutical (600223.SH) stated on the investor interaction platform that the company currently has no involvement in Retirement business.
Even With A 26% Surge, Cautious Investors Are Not Rewarding Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) Performance Completely
Private Companies Among Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) Largest Stockholders and Were Hit After Last Week's 5.4% Price Drop
Lushang Freda Pharmaceutical (600223.SH): Introducing the first AI digital spokesperson Cormier, reinforcing the concept of rejuvenating Ke Mei with technology.
Gelonghui November 21st, lushang freda pharmaceutical (600223.SH) stated on the investor interaction platform that lushang freda has always been exploring the development path of "technology beauty skin", taking the release of the Kemi brand as an opportunity to launch the first AI digital spokesperson Cormier, strengthening the concept of rejuvenating Kemi with "technology beauty sculpting".
Lushang Freda Pharmaceutical (600223.SH): Promoting cooperation with high-quality industry anchors and integrating special resources.
Gelonghui November 21st | Lushang Freda (600223.SH) stated on the investor interactive platform that the company has carried out a series of deployments around expanding through platforms like Douyin, optimizing product structure, innovating service mechanisms, strengthening full industry chain synergy, while enhancing the refinement level of self-broadcasting, promoting cooperation with industry's high-quality anchors and integrating special resources.
Despite the Downward Trend in Earnings at Lushang Freda PharmaceuticalLtd (SHSE:600223) the Stock Climbs 5.4%, Bringing Five-year Gains to 157%
